^
Association details:
| Biomarker: | EML4-ALK variant 1 |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences
Published date:
08/28/2022
Excerpt:
An ALK fusion variant was identified in 73% of the cases...In three specimens, four new EML4-ALK fusion breakpoints have been reported....The presence of V1 variant was associated with progression-free survival (PFS) improvement when crizotinib was used (p = 0.0073)…
DOI:
https://doi.org/10.1016/j.ejca.2022.07.026
Source:
Title:
Prevalence and Clinical Impact of Concomitant Mutations in Anaplastic Lymphoma Kinase Rearrangement Advanced Non-small-Cell Lung Cancer (Guangdong Association of Thoracic Oncology Study 1055)
Published date:
08/21/2020
Excerpt:
A total 132 patients with ALK rearrangement advanced NSCLC from 4 centers in Guangdong province, China were evaluated. All patients received crizotinib treatment...Secondly, according to the EML4-ALK rearrangement, we divided patients into variant 1, variant 3a/b, and other variant groups. The baseline characteristics of these three groups were well-balanced (Supplementary Table 2). The median PFS was similar in the three groups. In the variant 1 group the median PFS was 12.2 months (95% CI 9.2–23.5); in the variant 3a/b group, it was 12.3 months (95% CI 7.5–14.2).
DOI:
10.3389/fonc.2020.01216
